obesity

News

Lilly says 2026 looks good, as sales rocket in Q4

Eli Lilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed heavily on Novo Nordisk.

News

Lilly names Pennsylvania site for its latest US facility

Eli Lilly has revealed the fourth new manufacturing site in its $27 billion capital investment spree in the US - a $3.5bn facility in Pennsylvania.

News

AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal

AstraZeneca deepens ties with China, pledging $15bn in investment and signing a big $18.5bn alliance with CSPC Pharma for obesity and diabetes drugs.

News

Roche claims midstage win for obesity injectable

Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?

News

Wegovy pill shows strong early uptake, as rival looms

Encouraging early sales data for oral Wegovy has buoyed Novo Nordisk, as Lilly waits for an FDA decision on its rival orforglipron, now due in Q2.

News

JPM: Novo Nordisk CEO gives insight into new strategy

Novo Nordisk CEO Mike Doustdar covers oral Wegovy, DTC sales channels, and an under-appreciated obesity pipeline in a wide-ranging presentation.

Lilly says 2026 looks good, as sales rocket in Q4

Lilly names Pennsylvania site for its latest US facility

AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal

Roche claims midstage win for obesity injectable

Wegovy pill shows strong early uptake, as rival looms

JPM: Novo Nordisk CEO gives insight into new strategy

FDA greenlights Regeneron drug for rare bone disease

Discover a new era of healthcare panel engagement: Grounded ...

obesity

Editor's Picks